Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-10383
Fried, R; Monnat, M; Seidenberg, A; Oppliger, R; Schmid, P; Herold, M; Isler, M; Broers, B; Kölliker, C; Schönbucher, P; Frei, M; Huber, M (2008). Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion, 78(2-3):123-130.
- Registered users only
BACKGROUND: Though patients in opiate substitution programs are commonly infected with HCV, due to safety and efficacy concerns, they are rarely treated with interferon and ribavirin. METHODS: In a multicenter study, HCV-infected patients in opiate maintenance treatment programs received 180 microg pegylated interferon-alfa-2a once weekly, plus daily ribavirin for 24 weeks (genotypes 2, 3), or 48 weeks (genotypes 1, 4). RESULTS: Of the 67 patients enrolled, 31 (46%) had HCV genotypes 1 or 4, and 36 (54%) had genotypes 2 or 3. Intent-to-treat analysis showed end-of-treatment virologic response in 75% of patients (81% of genotypes 2 or 3; 65% of genotypes 1 or 4), and a sustained virologic response in 61% of patients (72% of genotypes 2 or 3; 48% of genotypes 1 or 4). Fifteen patients (22%) did not complete the study, in 5 (8%) cases because of severe adverse events. CONCLUSIONS: Drug users with chronic HCV infection, regularly attending an opiate maintenance program in which close collaboration between hepatologists/internists and addiction specialists is assured, can be treated effectively and safely with pegylated interferon-alfa-2a and ribavirin. Treatment results are very similar to those in other patient groups, and thus therapy should also be considered for this population.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Psychiatric University Hospital Zurich > Clinic for Clinical and Social Psychiatry Zurich West (former)|
04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
|DDC:||610 Medicine & health|
|Deposited On:||21 Jan 2009 14:47|
|Last Modified:||28 Nov 2013 00:06|
|Citations:||Web of Science®. Times Cited: 10|
Scopus®. Citation Count: 11
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page